HistCite - Trojanowski w/citing papers

Add FileX ?

Use wildcard '*' to add more than one file at a time. For example, if you have file1, file2, etc. all in the same folder or directory; first, locate one of the files with the [Browse...] button. Then alter the file path in the box above to include '*' character (eg. file*). Wildcard '?' to blanket only one character works too.
Note: In Windows you can select multiple files and "drag and drop" them onto HistCite icon or shortcut. The program would start and load those files.

#	Date / Author / Journal	LCS	GCS	LCR	CR
1	3546 Quinlan R, Hutchison C, Lane B Intermediate filament proteins PROTEIN PROFILE. 1995; 2 (8): 801-952	3	19	383	6003
2	3045 QUINLAN R, HUTCHISON C, LANE B INTERMEDIATE FILAMENT PROTEINS PROTEIN PROFILE. 1994; 1 (8): 779-911	5	29	380	5860
3	20113 Surguchov A MOLECULAR AND CELLULAR BIOLOGY OF SYNUCLEINS INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 270. 2008; 270: 225-317	6	12	320	420
4	12827 Arendt T Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity PROGRESS IN NEUROBIOLOGY. 2003 OCT; 71 (2-3): 83-248	17	65	314	3141
5	12467 Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease NEUROPHARMACOLOGY. 2003 JUL; 45 (1): 14-44	76	93	274	402
6	21170 Wang JZ, Liu F Microtubule-associated protein tau in development, degeneration and protection of neurons PROGRESS IN NEUROBIOLOGY. 2008 JUN; 85 (2): 148-175	22	45	259	404
7	21685 Uversky VN alpha-Synuclein Misfolding and Neurodegenerative Diseases CURRENT PROTEIN & PEPTIDE SCIENCE. 2008 OCT; 9 (5): 507-540	26	40	257	508
8	8535 Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR Tau protein isoforms, phosphorylation and role in neurodegenerative disorders BRAIN RESEARCH REVIEWS. 2000 AUG; 33 (1): 95-130	400	555	218	429
9	23661 Jellinger KA Recent advances in our understanding of neurodegeneration JOURNAL OF NEURAL TRANSMISSION. 2009 SEP; 116 (9): 1111-1162	12	25	215	609
10	18455 Chun W, Johnson GVW The role of tau phosphorylation and cleavage in neuronal cell death FRONTIERS IN BIOSCIENCE. 2007 JAN 1; 12: 733-756	8	18	212	334
#	Date / Author / Journal	LCS	GCS	LCR	CR
11	19656 Uversky VN Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation JOURNAL OF NEUROCHEMISTRY. 2007 OCT; 103 (1): 17-37	75	105	187	300
12	25085 Kovacs GG, Botond G, Budka H Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics ACTA NEUROPATHOLOGICA. 2010 APR; 119 (4): 389-408	4	4	186	246
13	8982 Lee VMY, Goedert M, Trojanowski JQ Neurodegenerative tauopathies ANNUAL REVIEW OF NEUROSCIENCE. 2001; 24: 1121-1159	807	807	178	256
14	21447 Perrot R, Berges R, Bocquet A, Eyer J Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration MOLECULAR NEUROBIOLOGY. 2008 AUG; 38 (1): 27-65	9	23	176	473
15	24959 Jellinger KA Basic mechanisms of neurodegeneration: a critical update JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2010 MAR; 14 (3): 457-487	0	0	169	460
16	22285 [Anon] Neuroanatomy and Pathology of Sporadic Parkinson's Disease NEUROANATOMY AND PATHOLOGY OF SPORADIC PARKINSON'S DISEASE. 2009; 201: 1-+	0	0	167	626
17	13729 Avila J, Lucas JJ, Perez M, Hernandez F Role of tau protein in both physiological and pathological conditions PHYSIOLOGICAL REVIEWS. 2004 APR; 84 (2): 361-384	73	157	166	309
18	25224 Lagier-Tourenne C, Polymenidou M, Cleveland DW TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration HUMAN MOLECULAR GENETICS. 2010 APR 15; 19: R46-R64	16	17	161	294
19	14972 Brandt R, Hundelt M, Shahani N Tau alteration and neuronal degeneration in tauopathies: mechanisms and models BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 331-354	45	65	160	228
20	22749 Gendron TF, Petrucelli L The role of tau in neurodegeneration MOLECULAR NEURODEGENERATION. 2009 MAR 11; 4: Art. No. 13	20	24	159	235
#	Date / Author / Journal	LCS	GCS	LCR	CR
21	26273 Vernon AC, Ballard C, Modo M Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of alpha-synuclein neuropathology required and feasible? BRAIN RESEARCH REVIEWS. 2010 OCT 5; 65 (1): 28-55	0	0	159	321
22	23609 Sen S, West AB The Therapeutic Potential of LRRK2 and alpha-Synuclein in Parkinson's Disease ANTIOXIDANTS & REDOX SIGNALING. 2009 SEP; 11 (9): 2167-2187	3	3	157	280
23	15183 Bennett MC The role of alpha-synuclein in neurodegenerative diseases PHARMACOLOGY & THERAPEUTICS. 2005 MAR; 105 (3): 311-331	42	67	156	216
24	23198 Ferrer I Early involvement of the cerebral cortex in Parkinson's disease: Convergence of multiple metabolic defects PROGRESS IN NEUROBIOLOGY. 2009 JUN; 88 (2): 89-103	2	8	155	279
25	23304 Di Napoli M New Molecular Avenues in Parkinson's Disease Therapy CURRENT TOPICS IN MEDICINAL CHEMISTRY. 2009 JUL; 9 (10): 913-948	1	1	153	298
26	25773 Noble W, Hanger DP, Gallo JM Transgenic Mouse Models of Tauopathy in Drug Discovery CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 AUG; 9 (4): 403-428	0	0	152	235
27	11220 Suh YH, Checler F Amyloid precursor protein, presenilins, and alpha-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease PHARMACOLOGICAL REVIEWS. 2002 SEP; 54 (3): 469-525	43	187	151	765
28	13170 Rademakers R, Cruts M, van Broeckhoven C The role of tau (MAPT) in frontotemporal dementia and related tauopathies HUMAN MUTATION. 2004; 24 (4): 277-295	92	102	150	195
29	23377 Robles A The complexes of degenerative dementias: an evolution from disease to spectrum NEUROLOGIA. 2009 JUL-AUG; 24 (6): 399-418	0	0	147	369
30	26210 Mackenzie IRA, Rademakers R, Neumann M TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia LANCET NEUROLOGY. 2010 OCT; 9 (10): 995-1007	3	4	143	203
#	Date / Author / Journal	LCS	GCS	LCR	CR
31	23276 Waxman EA, Giasson BI Molecular mechanisms of alpha-synuclein neurodegeneration BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2009 JUL; 1792 (7): 616-624	23	30	141	166
32	14190 Vekrellis K, Rideout HJ, Stefanis L Neurobiology of alpha-synulein MOLECULAR NEUROBIOLOGY. 2004 AUG; 30 (1): 1-21	32	42	140	175
33	14029 Bonifati V, Oostra BA, Heutink P Unraveling the pathogenesis of Parkinson's disease - the contribution of monogenic forms CELLULAR AND MOLECULAR LIFE SCIENCES. 2004 JUL; 61 (14): 1729-1750	12	29	139	278
34	22583 Cookson MR alpha-Synuclein and neuronal cell death MOLECULAR NEURODEGENERATION. 2009 FEB 4; 4: Art. No. 9	16	20	139	173
35	10325 Higuchi M, Lee VMY, Trojanowski JQ Tau and axonopathy in neurodegenerative disorders NEUROMOLECULAR MEDICINE. 2002; 2 (2): 131-150	46	46	137	226
36	8900 Forman MS, Lee VMY, Trojanowski JQ New insights into genetic and molecular mechanisms of brain degeneration in tauopathies JOURNAL OF CHEMICAL NEUROANATOMY. 2000 DEC; 20 (3-4): 225-244	32	32	136	191
37	14959 Sergeant N, Delacourte A, Buee L Tau protein as a differential biomarker of tauopathies BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 179-197	52	72	136	249
38	23807 Uversky VN, Eliezer D Biophysics of Parkinson's Disease: Structure and Aggregation of alpha- Synuclein CURRENT PROTEIN & PEPTIDE SCIENCE. 2009 OCT; 10 (5): 483-499	12	16	136	254
39	9635 Gotz J Tau and transgenic animal models BRAIN RESEARCH REVIEWS. 2001 JUL; 35 (3): 266-286	71	87	135	209
40	21319 Schneider A, Mandelkow E Tau-based treatment strategies in neurodegenerative diseases NEUROTHERAPEUTICS. 2008 JUL; 5 (3): 443-457	14	20	135	227
#	Date / Author / Journal	LCS	GCS	LCR	CR
41	23439 Neumann M, Tolnay M, Mackenzie IRA The molecular basis of frontotemporal dementia EXPERT REVIEWS IN MOLECULAR MEDICINE. 2009 JUL 29; 11: Art. No. e23	5	9	135	188
42	13282 Norris EH, Giasson BI, Lee VMY alpha-Synuclein: Normal function and role in neurodegenerative diseases STEM CELLS IN DEVELOPMENT AND DISEASE. 2004; 60: 17-54	58	70	134	256
43	26535 Badiola N, Suarez-Calvet M, Lleo A Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 DEC; 9 (6): 727-740	0	0	134	225
44	24276 Rabinovici GD, Miller BL Frontotemporal Lobar Degeneration Epidemiology, Pathophysiology, Diagnosis and Management CNS DRUGS. 2010; 24 (5): 375-398	1	1	133	244
45	26155 Gotz J, Gladbach A, Pennanen L, van Eersel J, Schild A, et al. Animal models reveal role for tau phosphorylation in human disease BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2010 OCT; 1802 (10): 860-871	4	4	131	187
46	23149 Uversky VN Intrinsic disorder in proteins associated with neurodegenerative diseases FRONTIERS IN BIOSCIENCE. 2009 JUN; 14: 5188-5238	8	18	130	526
47	5066 Billingsley ML, Kincaid RL Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration BIOCHEMICAL JOURNAL. 1997 MAY 1; 323: 577-591	118	200	129	213
48	19230 Gallo JM, Noble W, Martin TR RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies CELLULAR AND MOLECULAR LIFE SCIENCES. 2007 JUL; 64 (13): 1701-1714	5	8	128	161
49	19494 Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R Is alpha-synuclein pathology a target for treatment of neurodegenerafive disorders? CURRENT ALZHEIMER RESEARCH. 2007 SEP; 4 (4): 446-457	2	3	127	158
50	21709 Kim CY, Lee SJ Controlling the mass action of alpha-synuclein in Parkinson's disease JOURNAL OF NEUROCHEMISTRY. 2008 OCT; 107 (2): 303-316	6	11	127	190
#	Date / Author / Journal	LCS	GCS	LCR	CR
51	21892 Maguire-Zeiss KA alpha-Synuclein: A therapeutic target for Parkinson's disease? PHARMACOLOGICAL RESEARCH. 2008 NOV-DEC; 58 (5-6): 271-280	4	5	126	260
52	24143 Hatano T, Kubo S, Sato S, Hattori N Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease JOURNAL OF NEUROCHEMISTRY. 2009 DEC; 111 (5): 1075-1093	4	11	124	271
53	15533 Gong CX, Liu F, Grundke-Iqbal I, Iqbal K Post-translational modifications of tau protein in Alzheimer's disease JOURNAL OF NEURAL TRANSMISSION. 2005 JUN; 112 (6): 813-838	72	112	123	196
54	13983 von Bohlen und Halbach O, Schober A, Krieglstein K Genes, proteins, and neurotoxins involved in Parkinson's disease PROGRESS IN NEUROBIOLOGY. 2004 JUN; 73 (3): 151-177	14	61	122	303
55	18562 Woulfe JM Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2007 FEB; 33 (1): 2-42	7	15	122	357
56	14964 Goedert M, Jakes R Mutations causing neurodegenerative tauopathies BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 240-250	75	96	121	139
57	19485 Hernandez F, Avila J Tauopathies CELLULAR AND MOLECULAR LIFE SCIENCES. 2007 SEP; 64 (17): 2219-2233	25	40	121	210
58	21400 Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, et al. Tau as a biomarker of neuro degenerative diseases BIOMARKERS IN MEDICINE. 2008 AUG; 2 (4): 363-384	0	0	121	198
59	4786 Delacourte A, Buee L Normal and pathological tau proteins as factors for microtubule assembly INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 171. 1997; 171: 167-224	67	94	120	267
60	18262 Gasparini L, Terni B, Spillantini MG Frontotemporal dementia with tau pathology NEURODEGENERATIVE DISEASES. 2007; 4 (2-3): 236-253	17	21	120	157
#	Date / Author / Journal	LCS	GCS	LCR	CR
61	16430 Marklund N, Bakshi A, Castelbuono DJ, Conte V, McIntosh TK Evaluation of pharmacological treatment strategies in traumatic brain injury CURRENT PHARMACEUTICAL DESIGN. 2006; 12 (13): 1645-1680	9	35	119	608
62	21104 Uversky VN Amyloidogenesis of natively unfolded proteins CURRENT ALZHEIMER RESEARCH. 2008 JUN; 5 (3): 260-287	7	25	119	391
63	23252 Iqbal K, Liu F, Gong CX, Alonso AD, Grundke-Iqbal I Mechanisms of tau-induced neurodegeneration ACTA NEUROPATHOLOGICA. 2009 JUL; 118 (1): 53-69	31	56	118	216
64	23281 Cook C, Petrucelli L A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2009 JUL; 1792 (7): 664-675	4	10	118	236
65	23250 Duyckaerts C, Delatour B, Potier MC Classification and basic pathology of Alzheimer disease ACTA NEUROPATHOLOGICA. 2009 JUL; 118 (1): 5-36	15	29	116	353
66	8805 Grant P, Pant HC Neurofilament protein synthesis and phosphorylation JOURNAL OF NEUROCYTOLOGY. 2000 NOV; 29 (11-12): 843-872	30	75	115	266
67	18360 van Swieten J, Spillantini MG Hereditary frontotemporal dementia caused by Tau gene mutations BRAIN PATHOLOGY. 2007 JAN; 17 (1): 63-73	30	32	113	131
68	22677 Olivares D, Huang XD, Branden L, Greig NH, Rogers JT Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2009 MAR; 10 (3): 1226-1260	4	11	112	198
69	19142 Sun F, Kanthasamy A, Anantharam V, Kanthasamy AG Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease PHARMACOLOGY & THERAPEUTICS. 2007 JUN; 114 (3): 327-344	2	17	111	212
70	16782 Shults CW Lewy bodies PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006 FEB 7; 103 (6): 1661-1668	69	108	110	164
#	Date / Author / Journal	LCS	GCS	LCR	CR
71	7810 Lee VMY, Trojanowski JQ Distinct tau gene mutations induce specific dysfunctions/toxic properties in tau proteins associated with specific FTDP-17 phenotypes FATAL ATTRACTIONS: PROTEIN AGGREGATES IN NEURODEGENERATIVE DISORDERS. 2000; : 87-104	1	1	108	177
72	18363 Gotz J, Deters N, Doldissen A, Bokhari L, Ke YZ, et al. A decade of tau transgenic animal models and beyond BRAIN PATHOLOGY. 2007 JAN; 17 (1): 91-103	29	37	107	156
73	25774 Cavallarin N, Vicario M, Negro A The Role of Phosphorylation in Synucleinopathies: Focus on Parkinson's Disease CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 AUG; 9 (4): 471-481	1	1	107	159
74	14728 Moore DJ, West AB, Dawson VL, Dawson TM Molecular pathophysiology of Parkinson's disease ANNUAL REVIEW OF NEUROSCIENCE. 2005; 28: 57-87	146	354	106	185
75	18140 Beyer K Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane CELL BIOCHEMISTRY AND BIOPHYSICS. 2007; 47 (2): 285-299	16	25	106	151
76	21227 Jellinger KA A critical reappraisal of current staging of Lewy-related pathology in human brain ACTA NEUROPATHOLOGICA. 2008 JUL; 116 (1): 1-16	30	45	106	189
77	23285 Jellinger KA A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2009 JUL; 1792 (7): 730-740	13	13	106	185
78	25776 Hirth F Drosophila melanogaster in the Study of Human Neurodegeneration CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 AUG; 9 (4): 504-523	0	0	106	294
79	9304 Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, et al. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B- BIOLOGICAL SCIENCES. 2001 FEB 28; 356 (1406): 213-227	28	34	105	161
80	14726 Cookson MR The biochemistry of Parkinson's disease ANNUAL REVIEW OF BIOCHEMISTRY. 2005; 74: 29-52	119	234	105	151
#	Date / Author / Journal	LCS	GCS	LCR	CR
81	14963 Hall GF, Yao J Modeling tauopathy: a range of complementary approaches BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 224-239	8	8	105	138
82	21282 Bigio EH Update on recent molecular and genetic advances in frontotemporal lobar degeneration JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. 2008 JUL; 67 (7): 635-648	9	9	105	154
83	23792 Benedetto A, Au C, Aschner M Manganese-induced Dopaminergic Neurodegeneration: Insights into Mechanisms and Genetics Shared with Parkinson's Disease CHEMICAL REVIEWS. 2009 OCT; 109 (10): 4862-4884	0	4	105	462
84	10972 Planel E, Sun XY, Takashima A Role of GSK-3 beta in Alzheimer's disease pathology DRUG DEVELOPMENT RESEARCH. 2002 JUL; 56 (3): 491-510	16	38	104	233
85	14154 Chen F, David D, Ferrari A, Gotz J Posttranslational modifications of tau - Role in human tauopathies and modeling in transgenic animals CURRENT DRUG TARGETS. 2004 AUG; 5 (6): 503-515	25	36	104	140
86	23253 Zilka N, Korenova M, Novak M Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies ACTA NEUROPATHOLOGICA. 2009 JUL; 118 (1): 71-86	7	9	104	177
87	14606 Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, et al. Neurofilament proteins in neurodegenerative diseases CELLULAR AND MOLECULAR LIFE SCIENCES. 2004 DEC; 61 (24): 3057-3075	12	41	103	215
88	14955 Ko LW, DeTure M, Sahara N, Chihab R, Vega IE, et al. Recent advances in experimental modeling of the assembly of tau filaments BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 125-139	5	9	103	148
89	21408 Alonso AD, Li B, Grundke-Iqbal I, Iqbal K Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies CURRENT ALZHEIMER RESEARCH. 2008 AUG; 5 (4): 375-384	11	18	103	143
90	24513 Barmada SJ, Finkbeiner S Pathogenic TARDBP Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: Disease-Associated Pathways REVIEWS IN THE NEUROSCIENCES. 2010; 21 (4): 251-272	0	0	103	179
#	Date / Author / Journal	LCS	GCS	LCR	CR
91	24580 Hegde ML, Vasudevaraju P, Rao KJ DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease FRONTIERS IN BIOSCIENCE-LANDMARK. 2010 JAN; 15: 418-436	1	2	103	198
92	25785 van Rooijen BD, Claessens MMAE, Subramaniam V Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinson's Disease CURRENT PROTEIN & PEPTIDE SCIENCE. 2010 AUG; 11 (5): 334-342	0	0	103	164
93	21340 Robinson PA Protein stability and aggregation in Parkinson's disease BIOCHEMICAL JOURNAL. 2008 JUL 1; 413: 1-13	4	6	102	215
94	24550 Winklhofer KF, Haass C Mitochondrial dysfunction in Parkinson's disease BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2010 JAN; 1802 (1): 29-44	4	11	102	324
95	21837 Beyer K, Ariza A The Therapeutical Potential of Alpha-Synuclein Antiaggregatory Agents for Dementia with Lewy Bodies CURRENT MEDICINAL CHEMISTRY. 2008 NOV; 15 (26): 2748-2759	5	6	101	153
96	23606 Tan JMM, Wong ESP, Lim KL Protein Misfolding and Aggregation in Parkinson's Disease ANTIOXIDANTS & REDOX SIGNALING. 2009 SEP; 11 (9): 2119-2134	5	10	101	176
97	5059 Lovestone S, Reynolds CH The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes NEUROSCIENCE. 1997 MAY; 78 (2): 309-324	117	168	100	169
98	15228 Lundvig D, Lindersson E, Jensen PH Pathogenic effects of alpha-synuclein aggregation MOLECULAR BRAIN RESEARCH. 2005 MAR 24; 134 (1): 3-17	29	18	100	127
99	18239 Cacabelos R Molecular pathology and pharmacogenomics in Alzheimer's disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY. 2007; 29: 1-91	1	8	100	677
100	23925 Perrot R, Eyer J Neuronal intermediate filaments and neurodegenerative disorders BRAIN RESEARCH BULLETIN. 2009 OCT 28; 80 (4-5): 282-295	3	3	100	230

Date / Author / Journal

LCS

GCS

LCR

3546 Quinlan R, Hutchison C, Lane B

Intermediate filament proteins

PROTEIN PROFILE. 1995; 2 (8): 801-952

383

6003

3045 QUINLAN R, HUTCHISON C, LANE B

INTERMEDIATE FILAMENT PROTEINS

PROTEIN PROFILE. 1994; 1 (8): 779-911

380

5860

20113 Surguchov A

MOLECULAR AND CELLULAR BIOLOGY OF SYNUCLEINS

INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 270. 2008; 270: 225-317

320

420

12827 Arendt T

Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity

PROGRESS IN NEUROBIOLOGY. 2003 OCT; 71 (2-3): 83-248

314

3141

12467 Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H

Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease

NEUROPHARMACOLOGY. 2003 JUL; 45 (1): 14-44

274

402

21170 Wang JZ, Liu F

Microtubule-associated protein tau in development, degeneration and protection of neurons

PROGRESS IN NEUROBIOLOGY. 2008 JUN; 85 (2): 148-175

259

404

21685 Uversky VN

alpha-Synuclein Misfolding and Neurodegenerative Diseases

CURRENT PROTEIN & PEPTIDE SCIENCE. 2008 OCT; 9 (5): 507-540

257

508

8535 Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders

BRAIN RESEARCH REVIEWS. 2000 AUG; 33 (1): 95-130

400

555

218

429

23661 Jellinger KA

Recent advances in our understanding of neurodegeneration

JOURNAL OF NEURAL TRANSMISSION. 2009 SEP; 116 (9): 1111-1162

215

609

18455 Chun W, Johnson GVW

The role of tau phosphorylation and cleavage in neuronal cell death

FRONTIERS IN BIOSCIENCE. 2007 JAN 1; 12: 733-756

212

334

Date / Author / Journal

Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation

JOURNAL OF NEUROCHEMISTRY. 2007 OCT; 103 (1): 17-37

105

187

300

25085 Kovacs GG, Botond G, Budka H

Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics

ACTA NEUROPATHOLOGICA. 2010 APR; 119 (4): 389-408

186

246

8982 Lee VMY, Goedert M, Trojanowski JQ

Neurodegenerative tauopathies

ANNUAL REVIEW OF NEUROSCIENCE. 2001; 24: 1121-1159

807

178

256

21447 Perrot R, Berges R, Bocquet A, Eyer J

Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration

MOLECULAR NEUROBIOLOGY. 2008 AUG; 38 (1): 27-65

176

473

24959 Jellinger KA

Basic mechanisms of neurodegeneration: a critical update

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2010 MAR; 14 (3): 457-487

169

460

22285 [Anon]

Neuroanatomy and Pathology of Sporadic Parkinson's Disease

NEUROANATOMY AND PATHOLOGY OF SPORADIC PARKINSON'S DISEASE. 2009; 201: 1-+

167

626

13729 Avila J, Lucas JJ, Perez M, Hernandez F

Role of tau protein in both physiological and pathological conditions

PHYSIOLOGICAL REVIEWS. 2004 APR; 84 (2): 361-384

157

166

309

25224 Lagier-Tourenne C, Polymenidou M, Cleveland DW

TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration

HUMAN MOLECULAR GENETICS. 2010 APR 15; 19: R46-R64

161

294

14972 Brandt R, Hundelt M, Shahani N

Tau alteration and neuronal degeneration in tauopathies: mechanisms and models

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 331-354

160

228

22749 Gendron TF, Petrucelli L

The role of tau in neurodegeneration

MOLECULAR NEURODEGENERATION. 2009 MAR 11; 4: Art. No. 13

159

235

Date / Author / Journal

LCS

GCS

LCR

26273 Vernon AC, Ballard C, Modo M

Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of alpha-synuclein neuropathology required and feasible?

BRAIN RESEARCH REVIEWS. 2010 OCT 5; 65 (1): 28-55

159

321

23609 Sen S, West AB

The Therapeutic Potential of LRRK2 and alpha-Synuclein in Parkinson's Disease

ANTIOXIDANTS & REDOX SIGNALING. 2009 SEP; 11 (9): 2167-2187

157

280

15183 Bennett MC

The role of alpha-synuclein in neurodegenerative diseases

PHARMACOLOGY & THERAPEUTICS. 2005 MAR; 105 (3): 311-331

156

216

23198 Ferrer I

Early involvement of the cerebral cortex in Parkinson's disease: Convergence of multiple metabolic defects

PROGRESS IN NEUROBIOLOGY. 2009 JUN; 88 (2): 89-103

155

279

23304 Di Napoli M

New Molecular Avenues in Parkinson's Disease Therapy

CURRENT TOPICS IN MEDICINAL CHEMISTRY. 2009 JUL; 9 (10): 913-948

153

298

25773 Noble W, Hanger DP, Gallo JM

Transgenic Mouse Models of Tauopathy in Drug Discovery

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 AUG; 9 (4): 403-428

152

235

11220 Suh YH, Checler F

Amyloid precursor protein, presenilins, and alpha-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease

PHARMACOLOGICAL REVIEWS. 2002 SEP; 54 (3): 469-525

187

151

765

13170 Rademakers R, Cruts M, van Broeckhoven C

The role of tau (MAPT) in frontotemporal dementia and related tauopathies

HUMAN MUTATION. 2004; 24 (4): 277-295

102

150

195

23377 Robles A

The complexes of degenerative dementias: an evolution from disease to spectrum

NEUROLOGIA. 2009 JUL-AUG; 24 (6): 399-418

147

369

26210 Mackenzie IRA, Rademakers R, Neumann M

TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia

LANCET NEUROLOGY. 2010 OCT; 9 (10): 995-1007

143

203

Date / Author / Journal

LCS

GCS

LCR

23276 Waxman EA, Giasson BI

Molecular mechanisms of alpha-synuclein neurodegeneration

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2009 JUL; 1792 (7): 616-624

141

166

14190 Vekrellis K, Rideout HJ, Stefanis L

Neurobiology of alpha-synulein

MOLECULAR NEUROBIOLOGY. 2004 AUG; 30 (1): 1-21

140

175

14029 Bonifati V, Oostra BA, Heutink P

Unraveling the pathogenesis of Parkinson's disease - the contribution of monogenic forms

CELLULAR AND MOLECULAR LIFE SCIENCES. 2004 JUL; 61 (14): 1729-1750

139

278

22583 Cookson MR

alpha-Synuclein and neuronal cell death

MOLECULAR NEURODEGENERATION. 2009 FEB 4; 4: Art. No. 9

139

173

10325 Higuchi M, Lee VMY, Trojanowski JQ

Tau and axonopathy in neurodegenerative disorders

NEUROMOLECULAR MEDICINE. 2002; 2 (2): 131-150

137

226

8900 Forman MS, Lee VMY, Trojanowski JQ

New insights into genetic and molecular mechanisms of brain degeneration in tauopathies

JOURNAL OF CHEMICAL NEUROANATOMY. 2000 DEC; 20 (3-4): 225-244

136

191

14959 Sergeant N, Delacourte A, Buee L

Tau protein as a differential biomarker of tauopathies

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 179-197

136

249

23807 Uversky VN, Eliezer D

Biophysics of Parkinson's Disease: Structure and Aggregation of alpha- Synuclein

CURRENT PROTEIN & PEPTIDE SCIENCE. 2009 OCT; 10 (5): 483-499

136

254

9635 Gotz J

Tau and transgenic animal models

BRAIN RESEARCH REVIEWS. 2001 JUL; 35 (3): 266-286

135

209

21319 Schneider A, Mandelkow E

Tau-based treatment strategies in neurodegenerative diseases

NEUROTHERAPEUTICS. 2008 JUL; 5 (3): 443-457

135

227

Date / Author / Journal

LCS

GCS

LCR

23439 Neumann M, Tolnay M, Mackenzie IRA

The molecular basis of frontotemporal dementia

EXPERT REVIEWS IN MOLECULAR MEDICINE. 2009 JUL 29; 11: Art. No. e23

135

188

13282 Norris EH, Giasson BI, Lee VMY

alpha-Synuclein: Normal function and role in neurodegenerative diseases

STEM CELLS IN DEVELOPMENT AND DISEASE. 2004; 60: 17-54

134

256

26535 Badiola N, Suarez-Calvet M, Lleo A

Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 DEC; 9 (6): 727-740

134

225

24276 Rabinovici GD, Miller BL

Frontotemporal Lobar Degeneration Epidemiology, Pathophysiology, Diagnosis and Management

CNS DRUGS. 2010; 24 (5): 375-398

133

244

26155 Gotz J, Gladbach A, Pennanen L, van Eersel J, Schild A, et al.

Animal models reveal role for tau phosphorylation in human disease

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2010 OCT; 1802 (10): 860-871

131

187

23149 Uversky VN

Intrinsic disorder in proteins associated with neurodegenerative diseases

FRONTIERS IN BIOSCIENCE. 2009 JUN; 14: 5188-5238

130

526

5066 Billingsley ML, Kincaid RL

Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration

BIOCHEMICAL JOURNAL. 1997 MAY 1; 323: 577-591

118

200

129

213

19230 Gallo JM, Noble W, Martin TR

RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies

CELLULAR AND MOLECULAR LIFE SCIENCES. 2007 JUL; 64 (13): 1701-1714

128

161

19494 Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R

Is alpha-synuclein pathology a target for treatment of neurodegenerafive disorders?

CURRENT ALZHEIMER RESEARCH. 2007 SEP; 4 (4): 446-457

127

158

21709 Kim CY, Lee SJ

Controlling the mass action of alpha-synuclein in Parkinson's disease

JOURNAL OF NEUROCHEMISTRY. 2008 OCT; 107 (2): 303-316

127

190

Date / Author / Journal

LCS

GCS

LCR

21892 Maguire-Zeiss KA

alpha-Synuclein: A therapeutic target for Parkinson's disease?

PHARMACOLOGICAL RESEARCH. 2008 NOV-DEC; 58 (5-6): 271-280

126

260

24143 Hatano T, Kubo S, Sato S, Hattori N

Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease

JOURNAL OF NEUROCHEMISTRY. 2009 DEC; 111 (5): 1075-1093

124

271

15533 Gong CX, Liu F, Grundke-Iqbal I, Iqbal K

Post-translational modifications of tau protein in Alzheimer's disease

JOURNAL OF NEURAL TRANSMISSION. 2005 JUN; 112 (6): 813-838

112

123

196

13983 von Bohlen und Halbach O, Schober A, Krieglstein K

Genes, proteins, and neurotoxins involved in Parkinson's disease

PROGRESS IN NEUROBIOLOGY. 2004 JUN; 73 (3): 151-177

122

303

18562 Woulfe JM

Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2007 FEB; 33 (1): 2-42

122

357

14964 Goedert M, Jakes R

Mutations causing neurodegenerative tauopathies

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 240-250

121

139

19485 Hernandez F, Avila J

Tauopathies

CELLULAR AND MOLECULAR LIFE SCIENCES. 2007 SEP; 64 (17): 2219-2233

121

210

21400 Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, et al.

Tau as a biomarker of neuro degenerative diseases

BIOMARKERS IN MEDICINE. 2008 AUG; 2 (4): 363-384

121

198

4786 Delacourte A, Buee L

Normal and pathological tau proteins as factors for microtubule assembly

INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 171. 1997; 171: 167-224

120

267

18262 Gasparini L, Terni B, Spillantini MG

Frontotemporal dementia with tau pathology

NEURODEGENERATIVE DISEASES. 2007; 4 (2-3): 236-253

120

157

Date / Author / Journal

LCS

GCS

LCR

16430 Marklund N, Bakshi A, Castelbuono DJ, Conte V, McIntosh TK

Evaluation of pharmacological treatment strategies in traumatic brain injury

CURRENT PHARMACEUTICAL DESIGN. 2006; 12 (13): 1645-1680

119

608

21104 Uversky VN

Amyloidogenesis of natively unfolded proteins

CURRENT ALZHEIMER RESEARCH. 2008 JUN; 5 (3): 260-287

119

391

23252 Iqbal K, Liu F, Gong CX, Alonso AD, Grundke-Iqbal I

Mechanisms of tau-induced neurodegeneration

ACTA NEUROPATHOLOGICA. 2009 JUL; 118 (1): 53-69

118

216

23281 Cook C, Petrucelli L

A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2009 JUL; 1792 (7): 664-675

118

236

23250 Duyckaerts C, Delatour B, Potier MC

Classification and basic pathology of Alzheimer disease

ACTA NEUROPATHOLOGICA. 2009 JUL; 118 (1): 5-36

116

353

8805 Grant P, Pant HC

Neurofilament protein synthesis and phosphorylation

JOURNAL OF NEUROCYTOLOGY. 2000 NOV; 29 (11-12): 843-872

115

266

18360 van Swieten J, Spillantini MG

Hereditary frontotemporal dementia caused by Tau gene mutations

BRAIN PATHOLOGY. 2007 JAN; 17 (1): 63-73

113

131

22677 Olivares D, Huang XD, Branden L, Greig NH, Rogers JT

Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2009 MAR; 10 (3): 1226-1260

112

198

19142 Sun F, Kanthasamy A, Anantharam V, Kanthasamy AG

Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease

PHARMACOLOGY & THERAPEUTICS. 2007 JUN; 114 (3): 327-344

111

212

16782 Shults CW

Lewy bodies

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006 FEB 7; 103 (6): 1661-1668

108

110

164

Date / Author / Journal

LCS

GCS

LCR

7810 Lee VMY, Trojanowski JQ

Distinct tau gene mutations induce specific dysfunctions/toxic properties in tau proteins associated with specific FTDP-17 phenotypes

FATAL ATTRACTIONS: PROTEIN AGGREGATES IN NEURODEGENERATIVE DISORDERS. 2000; : 87-104

108

177

18363 Gotz J, Deters N, Doldissen A, Bokhari L, Ke YZ, et al.

A decade of tau transgenic animal models and beyond

BRAIN PATHOLOGY. 2007 JAN; 17 (1): 91-103

107

156

25774 Cavallarin N, Vicario M, Negro A

The Role of Phosphorylation in Synucleinopathies: Focus on Parkinson's Disease

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 AUG; 9 (4): 471-481

107

159

14728 Moore DJ, West AB, Dawson VL, Dawson TM

Molecular pathophysiology of Parkinson's disease

ANNUAL REVIEW OF NEUROSCIENCE. 2005; 28: 57-87

146

354

106

185

18140 Beyer K

Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane

CELL BIOCHEMISTRY AND BIOPHYSICS. 2007; 47 (2): 285-299

106

151

21227 Jellinger KA

A critical reappraisal of current staging of Lewy-related pathology in human brain

ACTA NEUROPATHOLOGICA. 2008 JUL; 116 (1): 1-16

106

189

23285 Jellinger KA

A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2009 JUL; 1792 (7): 730-740

106

185

25776 Hirth F

Drosophila melanogaster in the Study of Human Neurodegeneration

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2010 AUG; 9 (4): 504-523

106

294

9304 Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, et al.

From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B- BIOLOGICAL SCIENCES. 2001 FEB 28; 356 (1406): 213-227

105

161

14726 Cookson MR

The biochemistry of Parkinson's disease

ANNUAL REVIEW OF BIOCHEMISTRY. 2005; 74: 29-52

119

234

105

151

Date / Author / Journal

Modeling tauopathy: a range of complementary approaches

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 224-239

105

138

21282 Bigio EH

Update on recent molecular and genetic advances in frontotemporal lobar degeneration

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. 2008 JUL; 67 (7): 635-648

105

154

23792 Benedetto A, Au C, Aschner M

Manganese-induced Dopaminergic Neurodegeneration: Insights into Mechanisms and Genetics Shared with Parkinson's Disease

CHEMICAL REVIEWS. 2009 OCT; 109 (10): 4862-4884

105

462

10972 Planel E, Sun XY, Takashima A

Role of GSK-3 beta in Alzheimer's disease pathology

DRUG DEVELOPMENT RESEARCH. 2002 JUL; 56 (3): 491-510

104

233

14154 Chen F, David D, Ferrari A, Gotz J

Posttranslational modifications of tau - Role in human tauopathies and modeling in transgenic animals

CURRENT DRUG TARGETS. 2004 AUG; 5 (6): 503-515

104

140

23253 Zilka N, Korenova M, Novak M

Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies

ACTA NEUROPATHOLOGICA. 2009 JUL; 118 (1): 71-86

104

177

14606 Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, et al.

Neurofilament proteins in neurodegenerative diseases

CELLULAR AND MOLECULAR LIFE SCIENCES. 2004 DEC; 61 (24): 3057-3075

103

215

14955 Ko LW, DeTure M, Sahara N, Chihab R, Vega IE, et al.

Recent advances in experimental modeling of the assembly of tau filaments

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2005 JAN 3; 1739 (2-3): 125-139

103

148

21408 Alonso AD, Li B, Grundke-Iqbal I, Iqbal K

Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies

CURRENT ALZHEIMER RESEARCH. 2008 AUG; 5 (4): 375-384

103

143

24513 Barmada SJ, Finkbeiner S

Pathogenic TARDBP Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: Disease-Associated Pathways

REVIEWS IN THE NEUROSCIENCES. 2010; 21 (4): 251-272

103

179

Date / Author / Journal

LCS

GCS

LCR

24580 Hegde ML, Vasudevaraju P, Rao KJ

DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease

FRONTIERS IN BIOSCIENCE-LANDMARK. 2010 JAN; 15: 418-436

103

198

25785 van Rooijen BD, Claessens MMAE, Subramaniam V

Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinson's Disease

CURRENT PROTEIN & PEPTIDE SCIENCE. 2010 AUG; 11 (5): 334-342

103

164

21340 Robinson PA

Protein stability and aggregation in Parkinson's disease

BIOCHEMICAL JOURNAL. 2008 JUL 1; 413: 1-13

102

215

24550 Winklhofer KF, Haass C

Mitochondrial dysfunction in Parkinson's disease

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2010 JAN; 1802 (1): 29-44

102

324

21837 Beyer K, Ariza A

The Therapeutical Potential of Alpha-Synuclein Antiaggregatory Agents for Dementia with Lewy Bodies

CURRENT MEDICINAL CHEMISTRY. 2008 NOV; 15 (26): 2748-2759

101

153

23606 Tan JMM, Wong ESP, Lim KL

Protein Misfolding and Aggregation in Parkinson's Disease

ANTIOXIDANTS & REDOX SIGNALING. 2009 SEP; 11 (9): 2119-2134

101

176

5059 Lovestone S, Reynolds CH

The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes

NEUROSCIENCE. 1997 MAY; 78 (2): 309-324

117

168

100

169

15228 Lundvig D, Lindersson E, Jensen PH

Pathogenic effects of alpha-synuclein aggregation

MOLECULAR BRAIN RESEARCH. 2005 MAR 24; 134 (1): 3-17

100

127

18239 Cacabelos R

Molecular pathology and pharmacogenomics in Alzheimer's disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression

METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY. 2007; 29: 1-91

100

677

100

23925 Perrot R, Eyer J

Neuronal intermediate filaments and neurodegenerative disorders

BRAIN RESEARCH BULLETIN. 2009 OCT 28; 80 (4-5): 282-295

100

230

Trojanowski w/citing papers Publications by JQ Trojanowski and the papers citing JQ Trojanowski	Historiographs	Glossary HistCite Guide About Grand Totals: LCS 336329, GCS 1007154, CR 1762209 Collection span: 1973 - 2011
List of All Records